This can lead to fatigue, weakened immunity, or even chronic health issues
10.3389/fnut.2022.893344 22 HeC.HuangL.LeiP.LiuX.LiB.ShanY
The assay was performed in four ( Metro ) or five ( Metro-P3 ) biologically independent experiments with three technical replicates per experiment ( n = 45)
Regional Segment Analysis of the GLP-1 Receptor Agonist Market North America (U.S., Canada, Mexico) Europe (Germany, France, U.K., Italy, Spain, Rest of Europe) Asia-Pacific (China, Japan, India, Rest of APAC) South America (Brazil and the Rest of South America) The Middle East and Africa (UAE, South Africa, Rest of MEA) North America influenced the market with the largest market share over the forecast period Get more details on this report - Request Free Sample PDF North America is influencing significant market growth during the forecast period due to the region's high prevalence of chronic illnesses such as diabetes and obesity, rising R&D investments for creating novel pharmaceuticals for treating diabetes and obesity, the presence of significant companies, and the well-developed healthcare infrastructure
Compared with free curcumin, curcumin encapsulated in NPs demonstrates enhanced anti-proliferative effects [159], offering a promising strategy for breast cancer treatment
GLP-1 (glucagon-like peptide-1) receptor agonists mimic a natural gut hormone to slow digestion, reduce appetite, and regulate blood sugar
